Insulin aspart, recombinant Subcutaneous and Olopatadine nasal
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Olopatadine nasal and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: olopatadine nasal
Brand name: Patanase
Synonyms: Olopatadine (nasal), Olopatadine (Nasal)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Olopatadine Nasal Spray
- Insulin aspart, recombinant Subcutaneous-Olsalazine
- Insulin aspart, recombinant Subcutaneous-Olsalazine Sodium
- Insulin aspart, recombinant Subcutaneous-Olumiant
- Insulin aspart, recombinant Subcutaneous-Olux
- Insulin aspart, recombinant Subcutaneous-Olux-E
- Olopatadine nasal-Insulin degludec
- Olopatadine nasal-Insulin Degludec (U-100) Prefilled Pens
- Olopatadine nasal-Insulin Degludec (U-100) Vials
- Olopatadine nasal-Insulin Degludec (U-200) Prefilled Pens
- Olopatadine nasal-Insulin degludec and liraglutide
- Olopatadine nasal-Insulin degludec and liraglutide Subcutaneous